Stanford Type A Aortic Dissection Can Be Treated with Endoprosthesis

Original title: Endovascular Repair of Ascending Aortic Dissection. A Novel Treatment Option for Patients Judged Unfit for Direct Surgical Repair. Reference: Qingsheng Lu, et al. J Am Coll Cardiol 2013;61:1917–24.

The dissecting aneurysm Type A represents 60% or aortic dissections and a real challenge as regards both therapeutics and the adequate moment to perform it, due to the serious complications this pathology entails. This analysis included 41 patients admitted between 2009 and 2011 with aortic dissection type A; all of them received endovascular treatment due to high surgical risk. Exclusion criteria included:

No patient presented death or any other complication at hospital level, except for two that presented arrhythmias. Hospital stay was 3.3±1 days. Follow up was 26 months (16-35); intervention was repeated in one case only; no patient presented severe aortic insufficiency or death. Complete thrombosis of ascending aorta false lumen was noted in all 15 patients and descending aorta false lumen thrombosis was seen in 10 patients. There were no changes in ejection fraction or in left ventricle end-diastolic diameter; a significant reduction of proximal and distal aorta diameter was observed, and a significant increase in true lumen.

Conclusion: 

The endovascular treatment of the Ascending Aorta Type A was the appropriate option for patients considered poor candidates for conventional surgery.

Commentary: 

Being able to solve this pathology by endoprosthesis implantation, with good outcomes, encourages us to use this strategy in patients that are no candidates for surgery. An analysis made by Dr. Sobocinski in the year 2011 had concluded that half of patients could be treated with this technique, which invites us to investigate further and motivates us to develop new, more efficient devices, to cover a larger number of patients. 

Courtesy of Dr. Carlos Fava
Interventional cardiologist.
Favaloro Foundation Argentina.

Dr. Carlos Fava.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....